American College of Cardiology shares new guidelines for treating patients with anticoagulant and antiplatelet therapy – Cardiovascular Business

In fact, the ACC guidelines include a recommendation against the use of triple antithrombotictherapy for most patients and urges physicians to consider dual antithrombotictherapy consisting of an anticoagulant and a P2Y12 inhibitor when patients require both an anticoagulant and antiplatelet therapy following percutaneous coronary intervention (PCI).

Much of the guidance focusses on four clinical scenarios:

This is a complex topic, and we have attempted to cite the literature to offer direct guidance when possible and to highlight areas in which clinical judgement is needed, wrote writing committee chair Dharam J. Kumbhani, MD, an assistant professor of medicine at UT Southwestern Medical Center, and colleagues. We hope this document will aid in the management of this common yet challenging subset of patients.

Read the full recommendations here. A longer summary has also been published on the ACC website.

Read the original here:
American College of Cardiology shares new guidelines for treating patients with anticoagulant and antiplatelet therapy - Cardiovascular Business